Bard Logo

Investor Relations

BCR (Common Stock)
ExchangeNYSE (US Dollar)
Change (%) Stock is Down 1.01 (0.68%)
Data as of 08/28/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Featured Reports
Download Documentation2014 Proxy Statement
Download Documentation2013 Annual Report
Related Links
Corporate Governance
Contact the Bard Board of Directors
Recent NewsMore >>
07/24/14Bard Announces Second Quarter Results
MURRAY HILL, N.J.--(BUSINESS WIRE)--Jul. 24, 2014-- C. R. Bard, Inc. (NYSE:BCR) today reported 2014 second quarter financial results. Second quarter 2014 net sales were $827.1 million, an increase of 9 percent over the prior-year period on a reported basis. Excluding the impact of foreign exchange, second quarter 2014 net sales increased 8 percent over the prior-year period. For the second quarter 2014, net sales in the U.S. were $555.1 million, ... 
Printer Friendly Version
07/01/14Bard to Host Earnings Conference Call on July 24, 2014
MURRAY HILL, N.J.--(BUSINESS WIRE)--Jul. 1, 2014-- C. R. Bard, Inc. (NYSE: BCR) today announced that it will host a conference call on Thursday, July 24, 2014 at 5:00 PM EDT, to discuss the company’s second quarter 2014 operating results, and to provide financial guidance for the third quarter of 2014. Bard is scheduled to issue an earnings press release after the market closes on July 24, 2014. A live audio webcast of Bard's investor conference ... 
Printer Friendly Version
06/12/14Circulatory System Devices Advisory Panel Provides a Unanimous Favorable Recommendation to FDA for the Lutonix® Drug Coated Balloon
Lutonix® DCB one step closer to becoming the first FDA-approved drug coated balloon for the treatment of patients with femoropopliteal occlusive disease MURRAY HILL, N.J.--(BUSINESS WIRE)--Jun. 12, 2014-- C. R. Bard, Inc. (NYSE:BCR) today announced that the U.S. Food and Drug Administration’s (FDA) Circulatory System Devices Advisory Panel provided a unanimous favorable recommendation to FDA for use of the Lutonix® Drug Coated Balloon ... 
Printer Friendly Version
06/11/14Bard Announces $500 Million Share Repurchase Authorization
MURRAY HILL, N.J.--(BUSINESS WIRE)--Jun. 11, 2014-- The Board of Directors of C. R. Bard, Inc. (NYSE: BCR) today authorized the repurchase of up to $500 million of the company’s common stock. This is in addition to approximately $30 million remaining under the prior authorization announced in January 2014. Share repurchases will be made from time-to-time in the open market or through privately negotiated transactions. C. R. Bard, Inc. (www... 
Printer Friendly Version
Selected SEC Filings
Filing DateForm
07/25/1410-Q Download SEC Filing to Adobe PDF Download XBRL Content
04/23/1410-Q Download SEC Filing to Adobe PDF Download XBRL Content
02/19/1410-K Download SEC Filing to Adobe PDF Download XBRL Content
10/24/1310-Q Download SEC Filing to Adobe PDF Download XBRL Content
07/24/1310-Q Download SEC Filing to Adobe PDF Download XBRL Content
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever C. R. Bard, Inc. posts new information to the site. Just enter your e-mail address and click Submit.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.